Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | |
| Assets | ||
| Current Assets | ||
| Cash & Cash Equivalents | 70,103 | 24,547 |
| Marketable Securities | 48,098 | 66,817 |
| Other current assets | 2,025 | 1,005 |
| TOTAL | $120,226 | $92,369 |
| Non-Current Assets | ||
| PPE Net | 10,025 | 2,990 |
| Investments And Advances | 10,019 | 0 |
| Other Non-Current Assets | 188 | 178 |
| TOTAL | $20,232 | $3,168 |
| Total Assets | $146,520 | $107,731 |
| Liabilities | ||
| Current Liabilities | ||
| Accounts payable and accrued liabilities | 3,767 | 2,977 |
| Accrued Expenses | 7,599 | 3,258 |
| TOTAL | $13,818 | $7,489 |
| Non-Current Liabilities | ||
| Other Non-Current Liabilities | 185,714 | 101,380 |
| TOTAL | $185,892 | $101,406 |
| Total Liabilities | $211,411 | $121,479 |
| Shareholders' Equity | ||
| Retained earnings | -66,197 | -13,933 |
| Other shareholders' equity | -115 | 3 |
| TOTAL | $-64,891 | $-13,748 |
| Total Liabilities And Equity | $146,520 | $107,731 |